These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 36558928)

  • 21. A covalent strategy to target intrinsically disordered proteins: Discovery of novel tau aggregation inhibitors.
    Petri L; Ábrányi-Balogh P; Vagrys D; Imre T; Varró N; Mándity I; Rácz A; Wittner L; Tóth K; Tóth EZ; Juhász T; Davis B; Keserű GM
    Eur J Med Chem; 2022 Mar; 231():114163. PubMed ID: 35131537
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug discovery for a new generation of covalent drugs.
    Kalgutkar AS; Dalvie DK
    Expert Opin Drug Discov; 2012 Jul; 7(7):561-81. PubMed ID: 22607458
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Theory and applications of covalent docking in drug discovery: merits and pitfalls.
    Kumalo HM; Bhakat S; Soliman ME
    Molecules; 2015 Jan; 20(2):1984-2000. PubMed ID: 25633330
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reactivity of Covalent Fragments and Their Role in Fragment Based Drug Discovery.
    McAulay K; Bilsland A; Bon M
    Pharmaceuticals (Basel); 2022 Nov; 15(11):. PubMed ID: 36355538
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A targeted covalent inhibitor of p97 with proteome-wide selectivity.
    Ye Z; Wang K; Chen L; Jin X; Chen H; Tang G; Yao SQ; Feng Z; Zhang CJ
    Acta Pharm Sin B; 2022 Feb; 12(2):982-989. PubMed ID: 35256959
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting Epigenetic Regulators with Covalent Small-Molecule Inhibitors.
    Zhang Y; Rong D; Li B; Wang Y
    J Med Chem; 2021 Jun; 64(12):7900-7925. PubMed ID: 33599482
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Kinase-targeting small-molecule inhibitors and emerging bifunctional molecules.
    Goebel GL; Qiu X; Wu P
    Trends Pharmacol Sci; 2022 Oct; 43(10):866-881. PubMed ID: 35589447
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systematic Exploration of Privileged Warheads for Covalent Kinase Drug Discovery.
    Zhao Z; Bourne PE
    Pharmaceuticals (Basel); 2022 Oct; 15(11):. PubMed ID: 36355497
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Irreversible Kinase Inhibitors Targeting Cysteine Residues and their Applications in Cancer Therapy.
    Das D; Hong J
    Mini Rev Med Chem; 2020; 20(17):1732-1753. PubMed ID: 32400331
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular Recognition of FDA-Approved Small Molecule Protein Kinase Drugs in Protein Kinases.
    Zhu Y; Hu X
    Molecules; 2022 Oct; 27(20):. PubMed ID: 36296718
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Electrophilic warheads in covalent drug discovery: an overview.
    Péczka N; Orgován Z; Ábrányi-Balogh P; Keserű GM
    Expert Opin Drug Discov; 2022 Apr; 17(4):413-422. PubMed ID: 35129005
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advanced approaches of developing targeted covalent drugs.
    Gai C; Harnor SJ; Zhang S; Cano C; Zhuang C; Zhao Q
    RSC Med Chem; 2022 Dec; 13(12):1460-1475. PubMed ID: 36561076
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Road Map for the Structure-Based Design of Selective Covalent HCV NS3/4A Protease Inhibitors.
    Shunmugam L; Ramharack P; Soliman MES
    Protein J; 2017 Oct; 36(5):397-406. PubMed ID: 28815420
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology.
    Gehringer M; Laufer SA
    J Med Chem; 2019 Jun; 62(12):5673-5724. PubMed ID: 30565923
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estimating the binding energetics of reversible covalent inhibitors of the SARS-CoV-2 main protease: an
    Awoonor-Williams E
    Phys Chem Chem Phys; 2022 Oct; 24(38):23391-23401. PubMed ID: 36128834
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug discovery considerations in the development of covalent inhibitors.
    Mah R; Thomas JR; Shafer CM
    Bioorg Med Chem Lett; 2014 Jan; 24(1):33-9. PubMed ID: 24314671
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CovalentInDB: a comprehensive database facilitating the discovery of covalent inhibitors.
    Du H; Gao J; Weng G; Ding J; Chai X; Pang J; Kang Y; Li D; Cao D; Hou T
    Nucleic Acids Res; 2021 Jan; 49(D1):D1122-D1129. PubMed ID: 33068433
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drugging K-Ras
    Ni D; Li X; He X; Zhang H; Zhang J; Lu S
    Pharmacol Ther; 2019 Oct; 202():1-17. PubMed ID: 31233765
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Affinity and Selectivity Assessment of Covalent Inhibitors by Free Energy Calculations.
    Mihalovits LM; Ferenczy GG; Keserű GM
    J Chem Inf Model; 2020 Dec; 60(12):6579-6594. PubMed ID: 33295760
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Application of Dually Activated Michael Acceptor to the Rational Design of Reversible Covalent Inhibitor for Enterovirus 71 3C Protease.
    Ma Y; Li L; He S; Shang C; Sun Y; Liu N; Meek TD; Wang Y; Shang L
    J Med Chem; 2019 Jul; 62(13):6146-6162. PubMed ID: 31184893
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.